| 讲座 |
|
|
|
|
| 细胞移植治疗的兴起及实现途径——细胞移植治疗连载之一 |
| 王佃亮 |
| 第二炮兵总医院药学部 北京 100088 |
|
| The Origin and Implementation of Cell Transplantation Therapy |
| WANG Dian-liang |
| Department of Pharmacy, The Second Artillery General Hospital, Beijing 100088, China |
[1] Aduen J F, Castello R, Lazano M M, et al. An alternative echocardiographic method to estimate mean pulmonary artery pressure: diagnostic and clinical implications. J Am Soc Echocardiogr 2009,22:814-819.
[2] Bouhadir K H, Lee K Y, Alsberg E, et al. Degradation of partially oxidized alginate and its potential application for tissue engineering. Biotechnol Prog, 2001,17:945-950.
[3] Boyle A J, Schulman S P, Hare J M, et al. Is stem cell therapy ready for patients? Stem cell therapy for cardiac repair. Circulation, 2006,114:339-352.
[4] Breyer A, Estharabadi N, Oki M, et al. Multipotent adult progenitor cell isolation and culture procedures. Exp Hematol, 2006,34:1596-1601.
[5] Carpentino J E, Hynes M J, Appelman H D, et al. Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res, 2009,69(20):8208-8215.
[6] Chen F M, Zhang M, Wu Z F. Toward delivery of multiple growth factors in tissue engineering. Biomaterials, 2010,31:6279-6308.
[7] Chen Y, Teng F Y, Tang B L. Coaxing bone marrow stromal mesenchymal stem cells towards neuronal differentiation: progress and uncertainties. Cell Mol Life Sci, 2006,63:1649-1657.
[8] Ferdinandy P, Schulz R, Baxter G F. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and post conditioning. Pharmacol Rev, 2007,59:418-458.
[9] Hayashi S, Peranteau W H, Shaaban A F, et al. Complete allogeneic hema-topoietic chimerism achieved by a combined strategy of in utero hematopoietic stem cell transplantation and postnatal donor lymphocyte infusion. Blood, 2002,100:804-812.
[10] Hermann A, Liebau S, Gastl R, et al. Comparative analysis of neuroectodermal differentiation capacity of human bonemarrowstromal cells using various conversion protocols. J Neurosci Res, 2006,83:1502-1514.
[11] Ieda M, Fu J D, Delgado-Olguin P, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell ,2010,142:375-386.
[12] Jas X, D'Armini A M, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, placebo-controlled trial. J Am Coll Cardiol, 2008,52(25):2127-2134.
[13] Kawasaki B T, Hurt E M, Mistree T, et al. Targeting cancer stem cells with phytochemicals. Mol Interv, 2008,8(4):174-184.
[14] Zierold C, Carlson M A, Obodo U C, et al. Developing mechanistic insights into cardiovascular cell therapy: cardiovascular cell therapy research network biorepository core laboratory rationale. American Heart Journal, 2011, 162(6):973-980.
[15] Zhu, D L, Chen Li, Hong T. Position statement of the Chinese diabetes society regarding stem cell therapy for diabetes. Journal of Diabetes, 2012, 4(1):18-21.
[16] Assmus B, Fischer-Rasokat U, Honold J, et al. Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: Results of the TOPCARE-CHD registry. Circ Res, 2007,100:1234.
[17] Heldman A W, Hare J M. Cell therapy for myocardial infarction:special delivery. J Mol Cell Cardiol, 2007,44:473-476.
[18] Johnson P C, Mikos A G, Fisher J P, et al. Strategic directions in tissue engineering. Tissue Eng, 2007,13:2827-2837.
[19] von Bahr L, Sundberg B, Lunnies L, et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biology of Blood and Marrow Transplantation, 2012, 18 (4):557-564.
[20] Titomanlio L, Kavelaars A, Dalous J, et al. Stem cell therapy for neonatal brain injury: perspectives and challenges. Ann Neurol, 2011, 70(5):698-712. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
